Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.64 |
| ▸ | PPARA | Q07869 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13972896 | 0.98 | EPHX1 (0.68) | EPHX1PPARACA2CA1CA12 | |
| SCHEMBL10133161 | 0.93 | CA1 (0.58) | EPHX1PPARACA2CA1CA12 | |
| SCHEMBL5169582 | 0.83 | CA1 (0.55) | EPHX1PPARACA2CA1CA12 | |
| SCHEMBL12256385 | 0.81 | EPHX1 (0.75) | EPHX1PPARACA2CA1CA12 | |
| SCHEMBL12891809 | 0.81 | EPHX1 (0.75) | EPHX1PPARACA2CA1CA12 | |
| SCHEMBL1321109 | 0.80 | EPHX1 (0.96) | EPHX1PPARACA2CA1CA12 | |
| SCHEMBL1051783 | 0.79 | EPHX1 (0.41) | EPHX1PPARACA2CA1CA12 | |
| SCHEMBL13369989 | 0.78 | CYP2C19 (0.48) | EPHX1PPARACA2CA1CA12 | |
| SCHEMBL23862451 | 0.78 | EPHX1 (0.46) | EPHX1PPARAALDH1A1TSHRRELA | |
| SCHEMBL1318327 | 0.78 | EPHX1 (1.00) | EPHX1PPARACA2CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | EPHX1 3910/4885PPARA 1639/4885CA2 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.